C Butts
Overview
Explore the profile of C Butts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
743
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blitz M, Butts C, Kneteman N, Bigam D, Oosthuizen J, Phang P, et al.
Can J Surg
. 2023 Jun;
45(Suppl 3):3-26.
PMID: 37381180
No abstract available.
2.
Bebb D, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, et al.
Curr Oncol
. 2019 Sep;
26(4):e551-e557.
PMID: 31548824
The ros1 kinase is an oncogenic driver in non-small-cell lung cancer (nsclc). Fusion events involving the gene are found in 1%-2% of nsclc patients and lead to deregulation of a...
3.
Juergens R, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume M, et al.
Curr Oncol
. 2019 Jan;
25(6):384-392.
PMID: 30607113
Background: Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients...
4.
Melosky B, Cheema P, Agulnik J, Albadine R, Bebb D, Blais N, et al.
Curr Oncol
. 2018 Nov;
25(5):317-328.
PMID: 30464681
Background: Inhibition of the anaplastic lymphoma kinase (alk) oncogenic driver in advanced non-small-cell lung carcinoma (nsclc) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the...
5.
Vokes E, Ready N, Felip E, Horn L, Burgio M, Antonia S, et al.
Ann Oncol
. 2018 Feb;
29(4):959-965.
PMID: 29408986
Background: Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the...
6.
Cabanero M, Sangha R, Sheffield B, Sukhai M, Pakkal M, Kamel-Reid S, et al.
Curr Oncol
. 2017 May;
24(2):111-119.
PMID: 28490925
Starting in the early 2000s, non-small-cell lung cancer (nsclc) subtypes have evolved from being histologically described to molecularly defined. Management of lung adenocarcinomas now generally requires multiple molecular tests at...
7.
Kim J, Davis F, Butts C, Winget M
Clin Oncol (R Coll Radiol)
. 2016 Jul;
28(12):750-759.
PMID: 27357099
Aims: Very little is known regarding the time required to diagnose and treat patients with non-small cell lung cancer (NSCLC) in Canada. We sought to quantify diagnostic and treatment intervals...
8.
Melosky B, Agulnik J, Albadine R, Banerji S, Bebb D, Bethune D, et al.
Curr Oncol
. 2016 Jun;
23(3):196-200.
PMID: 27330348
Anaplastic lymphoma kinase (alk) is an oncogenic driver in non-small-cell lung cancer (nsclc). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead...
9.
Mitchell P, Thatcher N, Socinski M, Wasilewska-Tesluk E, Horwood K, Szczesna A, et al.
Ann Oncol
. 2015 Feb;
26(6):1134-1142.
PMID: 25722382
Background: Tecemotide is a MUC1-antigen-specific cancer immunotherapy. The phase III START study did not meet its primary end point but reported notable survival benefit with tecemotide versus placebo in an...
10.
Butts C, Kamel-Reid S, Batist G, Chia S, Blanke C, Moore M, et al.
Curr Oncol
. 2013 Oct;
20(5):e475-83.
PMID: 24155644
The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical decision-making, furthering prevention, surveillance, and...